Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician’s Choice Standard-of-Care Chemotherapy

por Rugo, Hope S, Ettl, Johannes, Hurvitz, Sara A, Gonçalves, Anthony, Lee, Kyung-Hun, Fehrenbacher, Louis, Mina, Lida A, Diab, Sami, Woodward, Natasha E, Yerushalmi, Rinat, Goodwin, Annabel, Blum, Joanne L, Martin, Miguel, Quek, Ruben G W, Tudor, Iulia Cristina, Bhattacharyya, Helen, Gauthier, Eric, Litton, Jennifer K, Eiermann, Wolfgang
Publicado 2019